Colorectal Cancer Therapeutics Market, By Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others), By Drug Class (Immunotherapy, Chemotherapy, and Targeted Therapy), By Sales Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), By Top Selling Drugs (5-Flurorouracil, Capecitabine, Irinotecan, Oxaliplatin, and Trifluridine & Tipiracil) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

The market for treatments for colorectal cancer was valued at US$ 9.8 billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 5.3% to reach US$ 16.36 billion by 2030. The market for treatments for colorectal cancer is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The global market for colorectal cancer therapies is now dominated by North America due to a number of factors, including an aging population, the most significant expenditure in pharmaceuticals and R&D departments, an expanding geriatric population, and more. Due to the rising incidence of colorectal cancer, poor eating habits, changing lifestyles, deteriorating food quality, etc., Asia Pacific is currently ranked second in this market. These factors will further contribute to the industry's growth.